Orna Therapeutics Acquires ReNAgade for Circular RNA Therapies
Shots:
- Under the acquisition, Orna will combine its circular RNA technology with ReNAgade’s LNP-based RNA delivery systems and comprehensive editing programs
- Acquistion will advance panCAR in vivo CAR RNA medicines for oncology and autoimmune diseases, vaccines in Merck’s partnership, and genetic disease programs
- Following acquisition, Orna Therapeutics and ReNAgade will bring substantial finance, as Orna raised $100M & $221M from Series A & Series B in Feb 2021 and Aug 2022, respectively, whereas ReNAgade raised $300M from Series A in May 2023
Ref: Orna Therapeutics | Image: Orna Therapeutics
Related News: Merck Collaborated with Orna Therapeutics to Advance RNA Therapies for Infectious Disease and Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
